Safety of insulin glargine use in pregnancy: A systematic review and meta-analysis

Annals of Pharmacotherapy

Volumn 45, Issue 1, 2011, Pages 9-16

  Pollex, Erika ^a,b   Moretti, Myla E ^c   Koren, Gideon ^c,d   Feig, Denice S ^e  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Hospital for Sick Children   (United Kingdom)

^d MOUNT SINAI HOSPITAL   (United States)

^e UNIVERSITY OF TORONTO   (Canada)

Author keywords

Gestational diabetes; Insulin glargine; NPH insulin; Pregnancy in diabetes; Type 1 diabetes; Type 2 diabetes

Indexed keywords

INSULIN GLARGINE;

ARTICLE; BIRTH INJURY; CONGENITAL MALFORMATION; DRUG SAFETY; GESTATIONAL AGE; HUMAN; HYPERBILIRUBINEMIA; HYPOGLYCEMIA; INTENSIVE CARE UNIT; MACROSOMIA; PERINATAL MORTALITY; PREGNANCY; PREGNANCY DIABETES MELLITUS; PREMATURE LABOR; PRIORITY JOURNAL; RESPIRATORY DISTRESS; SYSTEMATIC REVIEW;

DIABETES, GESTATIONAL; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; INSULIN; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MALE; PREGNANCY; PREGNANCY IN DIABETICS; PREGNANCY OUTCOME; RISK FACTORS;

EID: 78751559448     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P327     Document Type: Article

References (22)

1. Tyrala EE. The infant of the diabetic mother. Obstet Gynceol Clin North Am 1996;23:221-41. DOI 10.1016/S0889-8545(05)70253-9 (Pubitemid 26084173)
2. Kitzmiller JL, Gavin LA, Gin GD, Jovanovic-Peterson L, Main EK, Zigrang WD. Preconception care of diabetes: glycemic control prevents congenital anomalies. JAMA 1991;265:731-6. DOI 10.1001/jama.265.6.731
3. Mello G, Parretti E, Mecacci F, Pratesi M, Lucchetti R, Scarselli G. Excursion of daily glucose profiles in pregnant women with IDDM: relationship with perinatal outcome. J Perinat Med 1997;25:488-97. DOI 10.1515/jpme.1997.25. 6.488
4. ter Braak EW, Evers IM, Willem Erkelens D, Visser GH. Maternal hypoglycemia during pregnancy in type 1 diabetes: maternal and fetal consequences. Diabetes Metab Res Rev 2002;18:96-105. DOI 10.1002/dmrr.271 (Pubitemid 34467298)
5. Campbell RK, White JR, Levien T, Baker D. Insulin glargine. Clin Ther 2001;23:1938-57. DOI 10.1016/S0149-2918(01)80148-X (Pubitemid 34073187)
6. Owens DR, Coates PA, Luzio SD, Tinbergen JP, Kurzhals R. Pharmacokinetics of 125-I labelled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. Diabetes Care 2000;23:813-9. DOI 10.2337/diacare.23.6.813
7. Gough SCL. A review of human and analogue insulin trials. Diabetes Res Clin Pract 2007;77:1-15. DOI 10.1016/j.diabres.2006.10.015 (Pubitemid 46590471)
8. Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 study group. Diabetes Care 2000;23: 1130-6. DOI 10.2337/diacare.23.8. 1130
9. Feig DS, Razzaq A, Sykora K, Hux JE, Anderson GM. Trends in deliveries, prenatal care, and obstetrical complications in women with pregestational diabetes. Diabetes Care 2006;29:232-5.
10. Kurtzhals P, Schaffer L, Soresen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogues designed for clinical use. Diabetes 2000;49:999-1005.
11. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the reporting of observational studies in epidemiology (STROBE). Epidemiology 2007;18:805-35. DOI 10.1097/EDE.0b013e3181577511 (Pubitemid 350295185)
12. Heudo-Medina TB, Sanchez-Meca F, Marin-Martinez F, Botella J. Assessing heterogeneity in meta-analysis: I2 or Q statistic? Psychological Methods 2006;11:193-206. DOI 10.1037/1082-989X.11.2.193 (Pubitemid 44001277)
13. Poyhonen-Alho M, Ronnemaa T, Saltevo J, Ekblad U, Kaaja RJ. Use of insulin glargine during pregnancy. Acta Obstet Gynecol Scand 2007;86: 1171-4. DOI 10.1080/00016340701515282 (Pubitemid 47463728)
14. Price N, Bartlett C, Gillmer M. Use of insulin glargine during pregnancy: a case-control pilot study. BJOG 2007;114:453-7. DOI 10.1111/j.1471-0528.2006. 01216.x (Pubitemid 46393280)
15. Di Cianni G, Torlone E, Lencioni C, et al. Perinatal outcomes associated with the use of glargine during pregnancy. Diabetic Medicine 2008;25: 993-6. DOI 10.1111/j.1464-5491.2008.02485.x
16. Imbergamo MR, Amato MC, Sciortino G, et al. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study. Clin Ther 2008;30:1476-84. DOI 10.1016/j.clinthera.2008.08.013
17. Egerman R, Ramsey R, Kao L, et al. Perinatal outcomes in pregnancies managed with antenatal insulin glargine. Am J Perinatol 2009;26:591-5. DOI 10.1055/s-0029-1220782
18. Fang VYM, MacKeen D, Egan JFX, Zelop CM. Insulin glargine compared with neutral protamine hagedorn insulin in the treatment of pregnant diabetics. J Matern Fetal Neonatal Med 2009;22:249-53.
19. Smith JG, Manuck TA, White J, Merril DC. Insulin glargine versus neutral protamine hagedorn insulin for treatment of diabetes in pregnancy. Am J Perinatol 2009;26:57-62. DOI 10.1055/s-0028-1095181
20. Negrato CA, Rafacho A, Negrato G, et al. Glargine vs NPH insulin therapy in pregnancies complicated by diabetes: an observational cohort study. Diabetes Res Clin Pract 2010;89:46-51. DOI 10.1016/j.diabres.2010.03.015
21. Boskovic R, Feig DS, Derewlany L, Knie B, Portnoi G, Koren G. Transfer of insulin lispro across the human placenta: in vitro perfusion studies. Diabetes Care 2003;26:1390-4. DOI 10.2337/diacare.26.5.1390 (Pubitemid 36929168)
22. Pollex E, Feig D, Lubetsky A, Yip P, Koren G. The safety of insulin glargine in pregnancy: transplacental transfer studies. Diabetes Care 2010;33:29-33. DOI 10.2337/dc09-1045